Title BSC_company report_DCL_ICB 4577_ 04 03 2014
Report Type Phân tích công ty
Source BSC
Industry Health Care
Bussiness DCL
Detail Date : 10/03/2014
Total pages : 7
Language : English
File Type : .PDF
FileSize : 374 Kb
Download: 70
Download
Vote (You must be logged in to vote)
Short Content Company’s performance was flourished from 2011 to 2013: In 2011, the company lost nearly 31 billion dongs. Due to effective restructuring, up to Q2/2013, DCL had removed its accumulated losses. In 2013, the firm gained 36 billion dongs, up 86.32% over 2012, in which, its revenue increased 14.27%, its gross margin rose to 29.73% from 27.94%, its interest expense decreased 41% compared to 2012. DCL’s expected performance in 2014: We expect that its revenue will reach 750 billion dongs, up 7.28% over 2013. Gross profit margin is predicted to rise from 29.73% to 31.74% due to selling higher profit products. Financial expense reduced also push the increase in net income. We hope that the firm will reach 42 billion dongs of net income, equivalent to 4.201 dongs of EPS, up 18.98% compared to 2013. Investment points: DCL is a defensive stock with its beta less than 1, low liquidity so it is suitable for long-term investment. Its performance is improved because of effective restructuring and it is one of a few company that have P/B of 1.1 and P/E of 8. We recommend buying DCL with expected price next 12 months is 46.900 dongs per share.